Trial reportScientific reports2021
Association of blood pressure and renal outcome in patients with chronic kidney disease; a post hoc analysis of FROM-J study.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Education programmes for people with chronic kidney disease and diabetes.The Cochrane database of systematic reviews · 2024Pooled it
- Association of angiotensin receptor-neprilysin inhibitor therapy with changes in eGFR slope and home blood pressure in patients with chronic kidney disease.Clinical and experimental nephrology · 2026Article
- Transcriptomic Exploration of Tetrahydrocurcumin Effects in Chronic Kidney Disease.Biomedicines · 2026Article
- Renin-Angiotensin System Inhibitors in Patients With Nonproteinuric Chronic Kidney Disease and Kidney Outcomes: Findings From the CRIC Study.Kidney medicine · 2026Article
- Brazilian Guidelines of Hypertension - 2025.Arquivos brasileiros de cardiologia · 2025Article
- Role of Visfatin in Chronic Kidney Disease: Diagnostic Potential and Association with Hemodialysis.Reports of biochemistry & molecular biology · 2025Article
- Sacubitril/valsartan reduces proteinuria depending on blood pressure in patients with stage 4-5 chronic kidney disease.Clinical and experimental nephrology · 2024Article
- Systolic blood pressure, low-density lipoprotein cholesterol levels, and adverse kidney outcome: results from KNOW-CKD.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Observational
- Evaluation of transitions from early hypertension to hypertensive chronic kidney disease, coronary artery disease, stroke and mortality: a Thai real-world data cohort.Frontiers in cardiovascular medicine · 2023Article
- Review
- Renal Health Benefits of Rural City Planning in Japan.Frontiers in nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is well-known that hypertension exacerbates chronic kidney disease (CKD) progression, however, the optimal target blood pressure (BP) level in patients with CKD remains unclear. This study aimed to assess the optimal BP level for preventing CKD progression. The risk of renal outcome among different BP categories at baseline as well as 1 year after, were evaluated using individual CKD patient data aged between 40 and 74 years from FROM-J [Frontier of Renal Outcome Modifications in Japan] study. The renal outcome was defined as ≥ 40% reduction in estimated glomerular filtration rate to < 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.